ストックスクリーナーアプリを入手
9.75
9.30%
0.83
プレマーケット:
10.00
0.25
+2.56%
Zenas Biopharma Inc (ZBIO) 最新ニュース
ZENAS BIOPHARMA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Zenas BioPharma, Inc. and Encourages Investors to Contact the Firm - TradingView
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.
Press Release Distribution & PR Platform - ACCESS Newswire
Zenas BioPharma, Inc. Stockholder Notice: Robbins LLP Reminds Investors of the Class Action ... - Eagle-Tribune
Zenas BioPharma, Inc. Securities Fraud Class Action Lawsuit - GlobeNewswire
Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses - GlobeNewswire
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GuruFocus
ZBIO INVESTOR NOTICE: Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
Shareholders of Zenas BioPharma, Inc. Should Contact The Gross Law Firm Before June 16, 2025 to Discuss Your RightsZBIO - marketscreener.com
Contrasting Zenas Biopharma (ZBIO) & Its Competitors - Defense World
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm - The Bradford Era
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, - GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO - TradingView
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO - GlobeNewswire Inc.
Shareholder Alert: Robbins LLP Informs Stockholders of the Zenas BioPharma, Inc. Class Action Lawsuit - PR Newswire
ZBIO INVESTOR ALERT: Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
INVESTOR ALERT: Cohen Milstein Calls on Zenas BioPharma - GlobeNewswire
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Zenas BioPharma Faces Investor Suit Over Post-IPO Plunge - Law360
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - Business Wire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Zenas BioPharma, Inc. (ZBIO) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - TradingView
ZBIO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire
Reviewing Zenas Biopharma (ZBIO) and Its Peers - Defense World
ZBIO INVESTOR NEWS: ROSEN, THE FIRST FILING FIRM, - GlobeNewswire
ZBIO INVESTOR NEWS: ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to - Bluefield Daily Telegraph
ZBIO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
ZBIO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead the Zenas BioPharma Class Action Lawsuit - TradingView
ZBIO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Zenas BioPharma, Inc. – ZBIO - Business Wire
ZBIO Investor News: Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action InvestigationZBIO - PR Newswire
Zenas BioPharma, Inc. Announcement: If You Have Suffered - GlobeNewswire
Zenas BioPharma, Inc. Announcement: If You Have Suffered Losses in Zenas BioPharma, Inc. - Bluefield Daily Telegraph
Zenas BioPharma, Inc. Announcement: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - TradingView
Contrasting Zenas Biopharma (ZBIO) & The Competition - Defense World
Zenas BioPharma, Inc. Investor News: If You Have Suffered - GlobeNewswire
Zenas BioPharma, Inc. Investor News: If You Have Suffered Losses in Zenas BioPharma, Inc. - Bluefield Daily Telegraph
The Escalator: Rocket Pharmaceuticals, Zenas BioPharma, Angelini Ventures - Medical Marketing and Media
Critical Comparison: Zenas Biopharma (ZBIO) vs. Its Peers - Defense World
Zenas Biopharma (ZBIO) versus The Competition Head-To-Head Review - Defense World
Zenas Biopharma (ZBIO) and Its Competitors Financial Analysis - Defense World
Zenas BioPharma names Haley Laken as chief scientific officer - MSN
Zenas BioPharma names new Chief Scientific Officer By Investing.com - Investing.com South Africa
Zenas BioPharma names new Chief Scientific Officer - Investing.com Australia
Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst (NASDAQ:ZBIO) - Seeking Alpha
0.15%
4.32%
大文字化:
|
ボリューム (24 時間):